ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2024
ImmuCell (Nasdaq: ICCC) announced it will report unaudited financial results for Q3 2024 after market close on November 13, 2024. The company will host a conference call on November 14, 2024 at 9:00 AM ET to discuss the results. The company anticipates no changes to the preliminary sales results disclosed on October 8, 2024. ImmuCell develops and manufactures products improving health and productivity of dairy and beef cattle, including First Defense® for newborn calf immunity and Re-Tain® for subclinical mastitis treatment.
ImmuCell (Nasdaq: ICCC) ha annunciato che riporterà i risultati finanziari non auditati per il terzo trimestre 2024 dopo la chiusura del mercato il 13 novembre 2024. L'azienda condurrà una conferenza telefonica il 14 novembre 2024 alle 9:00 AM ET per discutere i risultati. L'azienda prevede che non ci saranno cambiamenti rispetto ai risultati di vendita preliminari divulgati l'8 ottobre 2024. ImmuCell sviluppa e produce prodotti che migliorano la salute e la produttività del bestiame da latte e da carne, incluso First Defense® per l'immunità dei vitelli neonati e Re-Tain® per il trattamento della mastite subclinica.
ImmuCell (Nasdaq: ICCC) anunció que reportará resultados financieros no auditados para el tercer trimestre de 2024 después del cierre del mercado el 13 de noviembre de 2024. La compañía llevara a cabo una conferencia telefónica el 14 de noviembre de 2024 a las 9:00 AM ET para discutir los resultados. La empresa anticipa que no habrá cambios en los resultados de ventas preliminares divulgados el 8 de octubre de 2024. ImmuCell desarrolla y fabrica productos que mejoran la salud y la productividad del ganado lechero y de carne, incluidos First Defense® para la inmunidad de los terneros recién nacidos y Re-Tain® para el tratamiento de la mastitis subclínica.
ImmuCell (Nasdaq: ICCC)는 2024년 3분기 개정된 재무 결과를 2024년 11월 13일 시장 마감 후 발표한다고 발표했습니다. 회사는 2024년 11월 14일 오전 9시(ET)에 결과를 논의하기 위해 컨퍼런스 콜을 개최할 것입니다. 회사는 2024년 10월 8일에 발표된 예비 판매 결과에 변경사항이 없을 것으로 예상하고 있습니다. ImmuCell은 신생 송아지 면역을 위한 First Defense®와 아증상 유방염 치료를 위한 Re-Tain®을 포함하여, 유제품 및 육류 가축의 건강과 생산성을 향상시키는 제품을 개발 및 제조합니다.
ImmuCell (Nasdaq: ICCC) a annoncé qu'elle publiera les résultats financiers non audités pour le troisième trimestre 2024 après la clôture des marchés le 13 novembre 2024. L'entreprise tiendra une conférence téléphonique le 14 novembre 2024 à 9h00 ET pour discuter des résultats. L'entreprise n'anticipe aucun changement par rapport aux résultats préliminaires des ventes divulgués le 8 octobre 2024. ImmuCell développe et fabrique des produits améliorant la santé et la productivité du bétail laitier et de viande, y compris First Defense® pour l'immunité des veaux nouveau-nés et Re-Tain® pour le traitement de la mastite subclinique.
ImmuCell (Nasdaq: ICCC) gab bekannt, dass es nach_marktschluss am 13. November 2024 unaudited Finanzzahlen für das 3. Quartal 2024 veröffentlichen wird. Das Unternehmen wird am 14. November 2024 um 9:00 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu diskutieren. Das Unternehmen erwartet keine Änderungen zu den vorläufigen Verkaufszahlen, die am 8. Oktober 2024 veröffentlicht wurden. ImmuCell entwickelt und produziert Produkte, die die Gesundheit und Produktivität von Milchkühen und Fleischrindern verbessern, einschließlich First Defense® zur Immunität von neugeborenen Kälbern und Re-Tain® zur Behandlung von subklinischer Mastitis.
- None.
- None.
Conference Call Scheduled for Thursday, November 14, 2024 at 9:00 AM ET
PORTLAND, Maine, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended September 30, 2024 after the market closes on Wednesday, November 13, 2024.
The Company is planning to host a conference call the next morning, Thursday, November 14, 2024, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until November 21, 2024 at (877) 344-7529 (toll free) or (412) 317-0088 (international), utilizing replay access code #6807288.
The Company anticipates no change to the preliminary sales results for the third quarter ended September 30, 2024 that were disclosed on October 8, 2024. The Company expects to file its Quarterly Report on Form 10-Q after the market closes on November 13, 2024.
Investors are encouraged to review the Company’s updated Corporate Presentation slide deck that provides an overview of the Company’s business which can be accessed under the “Investors” tab of the Company’s website at www.immucell.com, or by request to the Company. An updated version of the slide deck will be made available under the “Investors” tab of the Company’s website after the market closes on November 13, 2024.
About ImmuCell:
ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef calves. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is in the late stages of developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without FDA-required milk discard or meat withhold claims that provides an alternative to traditional antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com.
| Contacts: | Michael F. Brigham, President and CEO ImmuCell Corporation (207) 878-2770 Joe Diaz, Robert Blum and Joe Dorame Lytham Partners, LLC (602) 889-9700 iccc@lythampartners.com |
FAQ
When will ImmuCell (ICCC) release Q3 2024 financial results?
When is ImmuCell's (ICCC) Q3 2024 earnings conference call?
How can investors access ImmuCell's (ICCC) Q3 2024 earnings call?
What products does ImmuCell (ICCC) manufacture?
